Home  »  Technologies   »  Can You Get A Quick Recovery From AbCellera Biolog...

Can You Get A Quick Recovery From AbCellera Biologics Inc. (NASDAQ: ABCL) Given A -116.64% drop From High?

During the last session, AbCellera Biologics Inc. (NASDAQ:ABCL)’s traded shares were 4.16 million. At the end of the trading day, the stock’s price was $6.91, reflecting an intraday loss of -1.57% or -$0.11. The 52-week high for the ABCL share is $14.97, that puts it down -116.64 from that peak though still a striking 19.97% gain since the share price plummeted to a 52-week low of $5.53. The company’s market capitalization is $2.00B, and the average intraday trading volume over the past 10 days was 3.41 million shares, and the average trade volume was 1.92 million shares over the past three months.

AbCellera Biologics Inc. (ABCL) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. ABCL has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.13.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.

Sponsored

AbCellera Biologics Inc. (NASDAQ:ABCL) trade information

AbCellera Biologics Inc. (ABCL) registered a -1.57% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.57% in intraday trading to $6.91 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is 18.12%, and it has moved by 2.52% in 30 days. Based on these gigs, the overall price performance for the year is -4.82%. The short interest in AbCellera Biologics Inc. (NASDAQ:ABCL) is 24.53 million shares and it means that shorts have 17.54 day(s) to cover.

The consensus price target of analysts on Wall Street is $26.33, which implies an increase of 73.76% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $38.00 respectively. As a result, ABCL is trading at a discount of -449.93% off the target high and -117.08% off the low.

AbCellera Biologics Inc. (ABCL) estimates and forecasts

Statistics show that AbCellera Biologics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. AbCellera Biologics Inc. (ABCL) shares have gone down -50.57% during the last six months, with a year-to-date growth rate less than the industry average at -216.00% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -550.00% this quarter and then drop -275.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -89.80% compared to the previous financial year.

Revenue for the current quarter is expected to be $12.58 million as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to $12.67 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $45.92 million and $74.95 million respectively. In this case, analysts expect current quarter sales to shrink by -72.60% and then drop by -83.10% in the coming quarter.

While earnings are projected to return 4.40% in 2023, the next five years will return 10.00% per annum.

ABCL Dividends

AbCellera Biologics Inc. is due to release its next quarterly earnings between August 07 and August 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

AbCellera Biologics Inc. (NASDAQ:ABCL)’s Major holders

AbCellera Biologics Inc. insiders own 28.64% of total outstanding shares while institutional holders control 46.48%, with the float percentage being 65.13%. Baillie Gifford and Company is the largest shareholder of the company, while 276 institutions own stock in it. As of Mar 30, 2023, the company held over 19.83 million shares (or 6.87% of all shares), a total value of $149.52 million in shares.

The next largest institutional holding, with 13.69 million shares, is of Blackrock Inc.’s that is approximately 4.74% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $103.25 million.

Also, the Mutual Funds coming in first place with the largest holdings of AbCellera Biologics Inc. (ABCL) shares are Smallcap World Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2022 indicates that Smallcap World Fund owns about 5.48 million shares. This amounts to just over 1.90 percent of the company’s overall shares, with a $55.51 million market value. The same data shows that the other fund manager holds slightly less at 4.55 million, or about 1.58% of the stock, which is worth about $38.26 million.

On Key

Related Posts